Enjaymo

sutimlimab-jome

Approval

ApplicationBLA 761164
Approval dateFeb 4, 2022
Approval year2022
SponsorRecordati Rare Diseases, INC.

FDA-approved use

To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Enjaymo: